Coya Therapeutics' COYA 301 shows improved cognition and Treg expansion in Phase 1 AD study

Coya Therapeutics, Inc.

8 AD patients treated with monthly COYA 301 (low-dose IL-2) showed statistically significant improvement in MMSE scores (p=0.015) during treatment.
Treg percentage nearly doubled from 4.55% to 8.68% (p=0.0004); suppressive function increased from 46.6% to 79.5% (p=0.003).
Blood levels of pro-inflammatory cytokines IL-15, CCL2, and CCL11 were significantly lowered after each treatment cycle.
No serious adverse events; mild injection-site reactions and leukopenia; no patient discontinued the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.